P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.23 per share versus the Zacks Consensus Estimate of a loss of $3.29. This compares to a loss of $7.5 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this company would post a loss of $5 per share when it actually produced a loss of $6.28, delivering a surprise of -25.6%.Over the last four quarters, the company has n ...

P3 Health Partners (PIII) Q2 2025 Earnings Call August 14, 2025 04:30 PM ET Speaker0Good day, and welcome to the P3 Health Partners Second Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Ryan Holstead. Please go ahead.Speaker1Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

Exhibit 99.1 P3 Health Partners Announces Second Quarter 2025 Results Core Business Demonstrates Strength with Flat Medical Cost Trends Despite Industry Inflation $120-$170 Million in Additional EBITDA Opportunities Identified for 2026 Adjusted Full Year Guidance Reflects Prior Period Headwinds Management to Host Conference Call and Webcast August 14, 2025 at 4:30 PM ET The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to ...

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) (“P3” or the “Company”). (NASDAQ: PIII) Allegations and Investigation Focus: The investigation seeks to determine whether P3 Health Partners, and certain officers and directors, made false a ...

Core Viewpoint - P3 Health Partners Inc. (PIII) has experienced a bearish trend with a 13.1% stock price decline over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling a possible reversal if it appears at the bottom of the trend [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength is dependent on its placement on the chart [6]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for PIII, with a 7.8% increase in the consensus EPS estimate for the current year over the last 30 days, indicating that analysts expect better earnings than previously predicted [7][8]. - PIII holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are improving, further supporting the potential for a turnaround in PIII's stock performance [10].

Core Viewpoint - P3 Health Partners Inc. (PIII) is experiencing significant selling pressure, having declined 18.4% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory and analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key indicator used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - PIII's current RSI reading is 23.11, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for PIII have increased by 7.8% over the last 30 days, which often correlates with price appreciation [7]. - PIII holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.28 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $8 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.60%. A quarter ago, it was expected that this company would post a loss of $8.50 per share when it actually produced a loss of $16, delivering a surprise of -88.24%.Over the last four quarters, the company has not be ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $373 million, a 4% decrease from the prior year, primarily due to a decrease in membership [12][17] - Membership decreased by 8% year over year, aligning with the company's strategy to exit unprofitable plans [16][12] - Per member funding increased by 8% to $10.63 on a PMPM basis compared to the full year 2024, reflecting improved disease burden capture [12][17] - Adjusted operating expenses decreased by 18% sequentially and 11% year over year, indicating effective cost management [8][18] - Adjusted EBITDA for Q1 was a loss of $22 million, with a normalized loss of $13 million after accounting for a single underperforming contract [18][19] Business Line Data and Key Metrics Changes - The ACO reach population now accounts for approximately 15% of total membership, with a 60% increase in ACO membership over the past year [16][13] - The complex care program is projected to deliver over $30 million in savings for 2025 through improved care coordination [11][25] - Medical margin for Q1 was approximately $17 million or $49 PMPM, down from $37 million or $96 PMPM in Q1 2024 [17] Market Data and Key Metrics Changes - Three of the four markets achieved breakeven or better in Q1, with expectations for continued improvement [6][28] - Increased funding across markets by 8% on a PMPM basis indicates better disease burden capture [7][29] - The company is experiencing a steady ramp in converting groups into the Tier one category, with Oregon's Tier one enrollment expected to reach 60% by Q3 [11] Company Strategy and Development Direction - The company is executing a $130 million operating improvement plan, with a focus on operational efficiency, contracting, and execution [8][20] - Strategic initiatives are aimed at enhancing care enablement and improving provider engagement [10][24] - The company is actively renegotiating payer contracts to reduce exposure and improve funding [9][48] Management's Comments on Operating Environment and Future Outlook - Management remains confident in meeting full-year targets, citing improvements in operational metrics and payer collaboration [20][28] - The company is seeing positive impacts from benefit design changes, contributing to improved financial performance [29] - Despite industry headwinds, the company is reaffirming its guidance based on positive progress from various initiatives [28] Other Important Information - The company ended the quarter with approximately $40 million in cash, indicating a strong liquidity position [21] - The implementation of the Innovaccer system is on schedule, expected to enhance data infrastructure and analytics capabilities [26] Q&A Session Summary Question: Progress on the $130 million EBITDA initiative - The company achieved about 15% of the OpEx savings in Q1, with more benefits expected in the latter half of the year [34] Question: Engagement and satisfaction trends with the RESTORE program - The engagement strategy is working well, with key providers becoming ambassadors for the program [37] Question: Details on the outlier payer causing issues - The outlier payer accounts for no more than 22% of overall revenue, and the company is collaborating to rectify performance issues [41][42] Question: Trends in Medicare Advantage - The company is seeing improvements in utilization metrics, contrary to some public commentary about worsening trends [55] Question: Performance in the underperforming market - The underperforming market is associated with the outlier payer, but other payers in the same market are performing well [58][59]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $373 million, a 4% decrease from the prior year, primarily due to an 8% year-over-year decline in membership [11][15] - Average membership for Q1 2025 was approximately 116,000, down from 126,000 in Q1 2024, reflecting a strategic exit from unprofitable plans [14] - Per member funding increased by 8% to $10.63 on a PMPM basis compared to full year 2024, indicating improved capture of disease burden [11][15] - Adjusted operating expenses decreased by 18% sequentially and 11% year over year, reflecting efficiency improvements [7][17] - Adjusted EBITDA for Q1 2025 was a loss of $22 million, with a normalized loss of $13 million after accounting for a single underperforming contract [17][18] Business Line Data and Key Metrics Changes - The ACO reach population now accounts for approximately 15% of total membership, with a 60% increase in ACO membership over the past year [12][14] - The complex care program is projected to deliver over $30 million in savings for 2025 through improved care coordination [10][24] - Medical margin for Q1 2025 was approximately $17 million or $49 PMPM, compared to $37 million or $96 PMPM in Q1 2024 [15][17] Market Data and Key Metrics Changes - Three of the four markets achieved breakeven or better in Q1 2025, with expectations for continued improvement [6][27] - Increased funding across markets by 8% on a PMPM basis, indicating better financial performance [6][28] - The company is experiencing a steady ramp in converting groups into the Tier one category, with Oregon's enrollment expected to reach 60% by Q3 [10] Company Strategy and Development Direction - The company is executing a $130 million operating improvement plan, with a focus on operational efficiency, contracting, and execution [7][19] - Strategic initiatives include renegotiating payer contracts to reduce Part D exposure and improve funding [8][49] - The care enablement model is gaining momentum, aimed at reducing medical expenses and improving outcomes through enhanced data sharing and decision-making tools [9][24] Management's Comments on Operating Environment and Future Outlook - Management remains confident in meeting full-year targets, citing positive progress from strategic initiatives [19][27] - The company is addressing performance issues with a single outlier payer, with expectations for improvements in 2026 [6][27] - Overall, management sees encouraging trends in Medicare Advantage, with improved utilization metrics and funding structures [56][57] Other Important Information - The company ended Q1 2025 with approximately $40 million in cash, actively managing liquidity [20] - The implementation of the Innovaccer system is on schedule for complete deployment by mid-summer, enhancing data infrastructure and analytics capabilities [26] Q&A Session Summary Question: Progress on the $130 million EBITDA initiative - The company achieved roughly one-fifth of the OpEx savings in Q1, with more benefits expected in the latter half of 2025 [33][34] Question: Engagement and satisfaction trends with the RESTORE program - The engagement strategy is working well, with key providers becoming ambassadors for the program [36][37] Question: Details on the outlier payer causing issues - The outlier payer accounts for no more than 22% of overall revenue, with cost pressures primarily related to inpatient services from 2024 [42][44] Question: Trends in Medicare Advantage - The company is seeing improvements in utilization and benefit structures, contrary to negative trends reported by other payers [56][57]